Single-domain antibodies and variants thereof against pd-l1
A single-domain antibody, PD-L1 technology, applied in the direction of antibodies, antibody medical components, anti-animal/human immunoglobulin, etc., can solve problems such as unmet medical needs and uncommercialization
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment approach 1
[0347] Embodiment 1 is an isolated anti-PD-L1 construct comprising a single domain antibody (sdAb) portion that specifically recognizes PD-L1, wherein the sdAb portion comprises CDR1, CDR2 and CDR3, and said CDR1 comprises SEQ The amino acid sequence of any one of ID NO: 51-100 or a variant thereof comprising up to about 3 amino acid substitutions, said CDR2 comprising the amino acid sequence of any one of SEQ ID NO: 151-200 or a variant thereof comprising up to about 3 A variant of amino acid substitutions, the CDR3 comprising the amino acid sequence of any one of SEQ ID NO: 251-300 or a variant comprising up to about 3 amino acid substitutions.
Embodiment approach 2
[0348] Embodiment 2 is the isolated anti-PD-L1 construct of embodiment 1, wherein the sdAb portion comprises CDR1 comprising the amino acid sequence of any one of SEQ ID NO: 51-100; comprising any one of SEQ ID NO: 151-200 The amino acid sequence of CDR2 and CDR3 comprising the amino acid sequence of any one of SEQ ID NO: 251-300; or a variant thereof, the variant comprising up to about 3 amino acid substitutions in the plurality of CDR regions.
Embodiment approach 3
[0349] Embodiment 3 is the isolated anti-PD-L1 construct of any of embodiments 1-2, wherein the sdAb portion comprises any of the following:
[0350] (1) CDR1 comprising the amino acid sequence of SEQ ID NO: 51; CDR2 comprising the amino acid sequence of SEQ ID NO: 151; and CDR3 comprising the amino acid sequence of SEQ ID NO: 251; or a variant thereof, the variant being The plurality of CDR regions comprise up to about 3 amino acid substitutions;
[0351] (2) CDR1 comprising the amino acid sequence of SEQ ID NO: 52; CDR2 comprising the amino acid sequence of SEQ ID NO: 152; and CDR3 comprising the amino acid sequence of SEQ ID NO: 252; or a variant thereof, the variant being The plurality of CDR regions includes up to about 3 amino acid substitutions;
[0352] (3) CDR1 comprising the amino acid sequence of SEQ ID NO: 53; CDR2 comprising the amino acid sequence of SEQ ID NO: 153; and CDR3 comprising the amino acid sequence of SEQ ID NO: 253; or a variant thereof, the variant being ...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


